Tag Archives: undefined

DTE Energy: Bearish Sentiment And Solid Earnings Potential Make This Utility Look Undervalued

Summary Electric and natural gas utility DTE Energy’s share price has fallen in recent months despite strong earnings and management guidance. Environmental regulations are requiring the company to incur large expenses as it moves away from coal-fired capacity but it has the cash flow and liquidity to handle these. Furthermore, the economy in its service area is rebounding as Michigan’s unemployment rate has plummeted to the national average from its 2010 highs. Finally, the company is also investing in new capacity and is expanding its non-regulated operations so as to ensure sustained earnings and dividend growth over the next several years. Macroeconomic pressures have pushed the company’s share price close to the level at which they would be clearly undervalued and I would consider buying. The share price of electric and natural gas utility DTE Energy (NYSE: DTE ) has fallen by roughly 20% since the end of January (see figure) as the company has been hit by bearish sentiment on a number of fronts, including an expected rate increase from the Federal Reserve, weather during the first quarter that was warmer than during the same quarter of the previous year, and a combination of state and federal environmental regulations that have placed pressure on utilities to replace coal with natural gas and renewables. At the same time, however, the price decline has coincided with two consecutive quarterly earnings beats, low energy prices, and signs of a rebounding economy in the company’s service area. This article evaluates DTE Energy as a potential investment opportunity in light of this operating environment. DTE data by YCharts DTE Energy at a glance DTE Energy generates and distributes multiple types of energy from various pathways in the state of Michigan. The company was formed by the 2001 merger of the electric utility Detroit Edison Co. and the natural gas utility Michigan Consolidated Co. The two utilities now comprise DTE Energy’s two largest subsidiaries and operating segments under the names DTE Energy Electric Co. (“DTE Electric”) and DTE Gas Co. (“DTE Gas”). DTE Electric serves southeast Michigan, including Detroit and the surrounding area, generating electricity that it transmits to approximately 2.1 million customers. The subsidiary owns and operates 11,084 MW of generating capacity. Of this, approximately 70% is coal-fired, 10% is gas-fired or renewable (primarily hydroelectric with a smaller amount of biomass-fired capacity), and 20% is nuclear, the latter comprising 30% of Michigan’s total nuclear capacity. The heavy reliance of DTE Electric on coal-fired capacity has become a burden in recent years as inexpensive natural gas has made that fuel a more attractive option than coal and regulations at the state and federal levels have discouraged coal’s combustion. The company is investing heavily to replace much of its existing coal capacity with natural gas (in part via the acquisition of new gas-fired facilities) and renewables (such as the conversion of existing coal-fired facilities to biomass). The company expects coal’s total share of generating capacity to fall from 70% to 30% by 2030, offset by an increase to the share of gas and renewables from 10% to 50%. DTE Gas distributes natural gas to 1.2 million customers across Michigan, including the Detroit and Upper Peninsula areas. The subsidiary owns and operates 278 storage wells equal to 34% of Michigan’s underground capacity. It primarily serves the northern Michigan and Upper Peninsula areas and also owns the small Citizens Gas Fuel natural gas utility. While DTE Electric and DTE Gas are responsible for the vast majority of DTE Energy’s consolidated earnings (84% in Q1, split roughly evenly between the two subsidiaries), the company also owns smaller non-utility segments, including a gas storage and pipelines segment and a power & industrial projects segment, which provide most of the rest of the consolidated earnings. Finally, the company also operates an energy trading segment, although its contribution to earnings is generally minimal. Higher energy prices caused DTE Energy’s revenue to soar by 40% from 2012 to $12.3 billion in FY 2014 (see table). Although this was partially offset by similar increases to input and operating costs, its operating income and net income reached post-recession highs last year. While continuous profitability is to be expected from regulated utilities, with regulators commonly setting rates high enough to allow the utilities to achieve returns of equity of around 10%, DTE Energy’s earnings growth has caused its share price to achieve performance not common among utilities, more than tripling between 2009 and 2015. DTE Energy Financials (non-adjusted) Q1 2015 Q4 2014 Q3 2014 Q2 2014 Q1 2014 Revenue ($MM) 2,984.0 3,078.0 2,595.0 2,698.0 3,930.0 Gross income ($MM) 1,586.0 1,749.0 1,476.0 1,422.0 1,775.0 Net income ($MM) 273.0 299.0 156.0 124.0 326.0 Diluted EPS ($) 1.53 1.69 0.88 0.70 1.84 EBITDA ($MM) 715.0 832.0 578.0 564.0 875.0 Source: Morningstar (2015) One reason for DTE Energy’s impressive performance has been its ability to maintain a solid balance sheet in the type of volatile operating conditions that have been present since 2010. The company has maintained a current ratio of around 1.2 over the last five years, regularly ending the fiscal year with roughly $50 million in cash reserves (see table), even as its total assets have increased by $1.5 billion more than its total liabilities. While the company maintains a large amount of long-term debt ($8.3 billion at the end of FY 2014), this is not uncommon for regulated utilities and the firm’s interest expenses have actually declined even as its total debt load has increased. Overall, DTE Energy has been a strong performer in a sector that has done well for itself on average in recent years. DTE Energy Balance Sheet (restated) Q1 2015 Q4 2014 Q3 2014 Q2 2014 Q1 2014 Total cash ($MM) 99.0 48.0 60.0 75.0 98.0 Total assets ($MM) 28,068.0 27,974.0 26,376.0 26,189.0 26,161.0 Current liabilities ($MM) 1,839.0 2,577.0 2,805.0 2,819.0 3,569.0 Total liabilities ($MM) 19,403.0 19,647.0 18,207.0 18,181.0 18,044.0 Source: Morningstar (2015) Q1 earnings report DTE Energy reported its Q1 earnings in late April, beating on the top line and missing on the bottom line. Revenue came in at $3.0 billion, down 24% from $3.9 billion the previous year and missing the analyst consensus by $550 million. The decline was mostly attributable to the presence of much lower energy prices in the most recent year compared to Q1 2014, which caused the company to reduce the prices charged to its customers. DTE Gas reduced its natural gas prices by 17% compared to the previous year while DTE Electric reduced its own rates by 6%. The 24% YoY decline was also due in part to the fact that Q1 2014 was Michigan’s coldest in 60 years, driving sales volumes at DTE Gas. Q1 2015 was still cold (the third coldest in the last 60 years), but warmer than the previous year. DTE Energy’s consolidated operating income fell to $461 million from $560 million the previous year, driven by reduced natural gas demand and the presence of lower prices. Cost of revenue fell 35% YoY, however, mostly offsetting these factors. Furthermore, operating expenses fell by 7% YoY as O&M fell substantially. This latter decline enabled the company to report net income of $273 million compared to $326 million the previous year, or diluted EPS of $1.53 versus $1.84 the previous year. Adjusted diluted EPS was $1.65 compared to $1.69 YoY due to an adjustment of $0.18 attributed to the Energy Trading segment, which beat the analyst consensus by $0.12. The relatively warm weather in Q1 had a pronounced impact on the company’s earnings: while DTE Electric’s EPS was virtually unchanged YoY, that of DTE Gas was $0.11 lower compared to the previous year. Finally, EBITDA came in at $715 million compared to $875 million the previous year. In all, then, it was a strong quarter for the company, with the negative annual comparison being the result of 2014’s historically cold Q1 rather than underperformance at the company itself in Q1 2015. DTE Energy’s balance sheet also remained in good shape at the end of Q1. Operating cash flow for the quarter rose from $532 million the previous year and $541 million the previous quarter to $747 million, allowing the company to repay $117 million in debt and making $240 million worth of acquisitions, all while maintaining its $0.69 quarterly dividend (3.7% yield at the time of writing). The company no longer has any short-term debt on its books, and it ended the quarter with $99 million in cash compared to $98 million at the end of Q1 2014. Outlook DTE Energy’s Q1 results were in-line with its expectations, and its management expects to achieve an adjusted EPS range for FY 2015 of $4.48-$4.72. While not as strong as its FY 2014 EPS, which was boosted by a very impressive weather-induced Q1 result, even the bottom of the range would place FY 2015 as the 2nd-strongest quarter since FY 2009. Investors have a number of reasons to be optimistic regarding the company’s short-term outlook, not least of which is Michigan’s rebound from the 2008 financial crisis and subsequent recession, both of which had a disproportionately painful impact on the state. Michigan’s unemployment rate, which as recently as 2010 was several percentage points higher than the U.S. unemployment rate, has made up ground recently and is now the same as the national average (see figure). While some of the decline in the state’s rate has been to emigration, the state’s economy has finally begun to rebound following Detroit’s bankruptcy. Michigan is not expected to become a major economic growth story in coming years, let alone return to its days as an industrial powerhouse, but the economic recovery will benefit DTE Energy by driving residential demand for electricity and natural gas at the very least, as well as industrial demand under a more optimistic scenario. Michigan Unemployment Rate data by YCharts The fall in electricity rates and natural gas prices that has occurred since August 2014 has also driven demand for both, and this boost could grow still further if natural gas prices remain lower or fall further still. The citygate price of natural gas in Michigan is currently 14% lower than at the same time a year ago (see figure), while residential and industrial consumption of natural gas are both up strongly over the same period. Environmental regulations restricting the use of coal for generating electricity will prevent the company from taking full advantage of this demand since a large percentage of its capital expenditures are aimed at replacing coal capacity rather than acquiring net increases to existing capacity, but it still intends to invest $450 million just in new capacity for DTE Electric in FY 2015. This will be financed by a combination of operating cash flows, the issuance of $850 million in equity by the end of FY 2017, and $1.9 billion in available liquidity that recently had its maturity extended to April 2020. DTE Electric continues to access debt at low interest rates, with management stating during the Q1 earnings call that its most recent 30-year bond issuance achieved the company’s lowest interest rate since the Eisenhower administration. DTE Energy is positioned to successfully invest $11.5 billion in capital expenditures through 2019, $7.5 billion of which will go toward acquiring new capacity and replacing coal with natural gas and renewables. Michigan Natural Gas Citygate Price data by YCharts Finally, DTE Energy is also positioning itself to take advantage of America’s recent status as a major producer of hydrocarbons by transporting energy from inland reserves to its customers in Michigan. The company has formed a partnership with Spectra Energy to build a 250-mile pipeline connecting the Marcellus and Utica shales with a pipeline hub in Michigan that in turn connects Ohio, Chicago, and Ontario. DTE Energy is contributing $700 million to the NEXUS pipeline, which is expected to be in service by Q4 2017. With 1.5 Bcf/day capacity, the pipeline will be an important addition to the region’s existing pipeline infrastructure when completed. There are still many hurdles to overcome, with regulators recently taking issue with the pipeline’s proposed route, but construction isn’t expected to begin for at least another year, at which point it will take only a year to complete. Valuation Not surprisingly, given management’s recent guidance, analyst estimates for DTE Energy’s diluted EPS in FY 2015 and FY 2016 have increased only very slightly over the last 90 days. The FY 2015 consensus has increased from $4.62 to $4.64 while the FY 2016 estimate has increased from $4.91 to $4.92. Based on the company’s share price at the time of writing of $74.34, its shares are trading at a trailing P/E ratio of 16.3x and forward ratios of 16.0 and 15.1, respectively. All of these ratios are in the bottom half of their 3-year historical ranges (see figure), although the forward ratios would need to fall below 14x before the company could be considered to be clearly undervalued. DTE PE Ratio (TTM) data by YCharts Conclusion DTE Energy’s share price has fallen substantially even though it has had a good year to date. Its shares certainly appear to be more attractive based on forward valuations than they were at the beginning of the year, a result that can be largely attributed to the prevalence of bearish sentiment toward dividend stocks in anticipation of one or more interest rate hikes by the Federal Reserve later in the year. With a 3.7% yield, an improved operating environment, and plans to increase regulated capacity while expanding its non-regulated operations, DTE Energy is an attractive long investment candidate. I think that interest rate expectations could push the company’s shares lower in the coming months, but I would consider purchasing its shares in the event that they fall below $69 (or 14x the FY 2016 consensus EPS) in the near future. Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in DTE over the next 72 hours. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

3 Small-Cap Growth ETFs To Buy For Q3

Contrary to popular believe, the Fed dove is still to fly far from the border of the U.S. economy. In its latest June meeting, the Fed remained accommodative and hinted at a slower rate hike trail when the step is actually taken. To add to this, the Fed slashed its projection for the benchmark interest rate for 2016 and 2017, though the guidance for the ongoing year was kept unchanged. This indirectly promised investors a few more months of cheap money inflows. On the other hand, the U.S. economy is taking root. Fed officials even went on to say that the rebounding U.S. economy is strong enough to endure one or two rate hikes this year and insisted that the rate hike decision will be solely economic data reliant. The ”soft patch” of Q1 has disappeared with “moderate” economic growth momentum in Q2. The economy wrote a turnaround story with better than expected job growth data along with strong construction spending, automobile sales and housing numbers. Some dampeners of Q1 including a harsh winter and strikes at the Western Coast ports will not be present in Q3, though a relatively stronger greenback (against a basket of currencies) might cause occasional threats to U.S. exports and the large-cap stocks. This economic development set the stage for the small-cap growth ETF’s outperformance. Small cap stocks are broadly leading the market higher this year and are comfortably surpassing their large cap cousins. The ultra-popular small cap ETF iShares Russell 2000 ETF (NYSEARCA: IWM ) is up 6.9% year to date (as of June 19, 2015) against 2.4% gains in the SPDR S&P 500 ETF Trust (NYSEARCA: SPY ) . This trend will likely continue in the coming quarter, presuming that a risk-on sentiment will hang on in the marketplace and the focus will stay on the domestically exposed stocks. Investors should note that small-cap stocks are seen as an indicator of the domestic economy. These pint-sized companies deal mainly with the domestic economy. Due to their less global exposure, these stocks remain relatively less ruffled by a strong dollar. So this part of capitalization would be one of the best bets if the Fed takes the rate hike plunge later on the year. Moreover, indecisiveness is prevalent in the global markets due to Greek debt worries, slowdown in China and Japan, rate issues in the U.S. and the consequent movement in the greenback and finally the volatility in oil prices. These happenings might weigh on large-cap stocks leaving small-cap growth stocks and ETFs as intriguing choices. These growth focused small caps have actually outperformed the broad market small cap ETFs lately by a pretty wide margin and have the potential to carry forward the trend. Small-Cap Growth ETFs Upgraded to Buy Rating Below, we highlight three small-cap growth ETFs all with Zacks Rank #1 (Strong Buy) or #2 (Buy), any of which could be an excellent play in the third quarter. Investors should note that each of these ETFs went through a Zacks rank upgrade recently. SPDR S&P 600 Small Cap Growth ETF (NYSEARCA: SLYG ) This ETF was upgraded from Zacks ETF Rank #3 (Hold) to Zacks ETF Rank #1. The ETF tracks the S&P SmallCap 600 Growth Index. Holding 351 securities, this fund is also well spread out across each sector and security. Each security accounts for less than 1.27%, while sector wise, Financials, Consumer Discretionary, Healthcare, Information Technology and Industrials take the top five spots each with double-digit exposure, leaving a decent allocation for the utilities and telecom sectors. This $575 million fund trades at a paltry volume of 20,000 shares a day suggesting additional cost beyond the expense ratio of 0.15%. The ETF is up 9.6% year to date (as of June 19, 2015). iShares Morningstar Small-Cap Growth ETF (NYSEARCA: JKK ) The product was upgraded from Zacks ETF Rank #3 to #2. This is an overlooked choice in the small cap space with AUM of $141.5 million and average trading volume of close to 2000 shares a day. The 252-stock fund tracks the Morningstar Small Growth Index. It is well spread out across components as none of these holds more than 1.15% of assets. Sector wise, information technology (28.90%), and healthcare (22%) take the top two spots. The fund charges 30 bps in annual fees from investors and has gained 10.4% so far this year. Guggenheim S&P SmallCap 600 Pure Growth ETF (NYSEARCA: RZG ) This ETF was upgraded from Zacks ETF Rank #3 to #1. The fund targets the small cap U.S. market and follows the S&P SmallCap 600 Pure Growth Index. Holding 132 securities in its basket, it is well spread out across components with each holding less than 2.17%. Financials, Healthcare, Consumer Discretionary, Information Technology, and Industrials are the top five sectors with double-digit allocation each. The fund has amassed $166 million in its asset base and trades in light volume of about 20,000 shares a day on average. Expense ratio comes in at 0.35%. The product has surged 14.5% so far in the year. Original Post

5 Stocks Leading XBI Biotech ETF Higher

The biotech corner of the health care space is having a stellar run like last year and still remains a favorite investment destination for investors. This is primarily thanks to strong earnings growth, merger & acquisition frenzy, promising drug launches, cost-cutting efforts, a rise in the aging population, insatiable demand for new drugs, ever-increasing health care spending, expansion into emerging markets and the Affordable Care Act or Obamacare. Further, biotech stocks provide a defensive tilt to the portfolio amid political or economic turmoil. While most of the biotech ETFs has given incredible performances so far in the year, the ultra-popular – SPDR S&P Biotech ETF (NYSEARCA: XBI ) – is not far behind. It is the third best performing ETF in the biotech space, returning nearly 39.5%. XBI in Focus With AUM of $2.3 billion and average daily volume of close to a million shares, XBI is extremely liquid and an easily traded fund. It provides equal weight exposure across 106 stocks by tracking the S&P Biotechnology Select Industry Index. This suggests that the product has no concentration issue and offers huge diversification benefits. The product has a definite tilt toward small cap securities, as mid and large caps account for only around 10% each. It charges a relatively low fee of 35 bps a year for the exposure and has a Zacks ETF Rank of 2 or ‘Buy’ rating with a High risk outlook. Several stocks in the ETF portfolio are worth noting, as these have been the real stars and have contributed much to its outstanding performance. Below, we have highlighted those five best performing stocks and each takes nearly 1% share in the fund’s basket, irrespective of its position: Best Performing Stocks of XBI Eagle Pharmaceuticals Inc. (NASDAQ: EGRX ): Based in Woodcliff Lake NJ, this specialty pharmaceutical company is focused on developing and commercializing injectable products, primarily in the critical care and oncology areas in the United States. Having a Zacks Rank of #3 (Hold), the stock surged nearly five-folds in the year-to-date time frame given its incredible growth prospect with a Growth Style Score of ‘A’. The company’s earnings are expected to grow a whopping 137.90% this year compared to industry growth projection of 9.75% and sales growth projection is also robust at 264.47% versus the industry average of 4.43%. The stock also has a solid Zacks Industry Rank in the top 39% at the time of writing. Heron Therapeutics Inc. (NASDAQ: HRTX ): Based in Redwood City, CA, this biotech company develops products using its proprietary Biochronomer polymer-based drug delivery platform to address unmet medical needs. The stock has delivered incredible returns of over 215% so far in the year and is still showing solid momentum with a Momentum Style Score of ‘A’. The stock has seen narrowing loss estimate from $2.78 per share to $2.56 per share over the past 60 days, suggesting some upside. This represents earnings growth of 10.9% year-over year, up from the industry average of 1.5% growth. HRTX has a Zacks Rank #3 and a solid Zacks Industry Rank in the top 41%. Exelixis Inc. (NASDAQ: EXEL ): The stock was recently upgraded by a notch to Zacks Rank #2 (Buy), and has climbed nearly 180% so far this year. Based in South San Francisco, the company develops and sells small molecule therapies for the treatment of cancer in the United States. Though the company’s earnings are expected to grow 42.79% year over year this year, well above the industry average of 6.43%, earnings yield is highly negative at 20.31% and worse than the industry average of 7.84%. As such, the stock currently does not pose ideal flavors of growth, value and momentum. However, it falls in a strong industry category, having a Zacks Rank in the top 42%. Retrophin Inc. (NASDAQ: RTRX ): Based in San Diego, CA, this biopharma company focuses on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The stock, with an industry Zacks Rank in the top 42%, has gained 177% in the year-to-date time frame. Though the company’s earnings and revenues are expected to grow more than the industry average this year, its growth and value prospects are gloomy with a Growth Style Score of ‘D’ and Value Style Score of ‘F’. This is because the stock has a Zacks Rank #4 (Sell) and seen massive negative estimate revisions from a loss of 96 cents per share to a loss of $1.64 per share for the current fiscal year. This suggests some pain for this company in the coming weeks. Prothena Corp Plc (NASDAQ: PRTA ): The stock has delivered robust returns of 159% so far this year but the trend of outperformance is likely to snap in the coming weeks. This is especially true as this Zacks Rank #3 stock also has a dull Growth and Value Style score of ‘F’ each despite the strong industry Zacks Rank in the top 42%. Earnings and revenues are expected to decline 796.5% and 95.3%, respectively, for this year. Based in Dublin, Ireland, Prothena is a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of protein immunotherapy programs for the treatment of diseases that involve amyloid or cell adhesion. Original Post